Covaxin (Stock code: 688136.SH): The first subject was dosed in the Phase I clinical trial of GB10 injection.

Chitrade Financial APP News, CoSci Pharma (688136.SH) announced that recently, the company's wholly-owned subsidiary Shenzhen CoSci Pharmaceutical Co., Ltd. ("Shenzhen CoSci") has successfully completed the first subject's dosing in the Phase I clinical study of the ophthalmic preparation "GB10 Injection" independently developed by Shenzhen CoSci.